CISPLATIN AND MITOMYCIN-C IN ADVANCED CHEMOTHERAPY-REFRACTORY BREAST-CANCER

被引：4

作者：

CRIVELLARI, D ^{[1
]}

GALLIGIONI, E ^{[1
]}

FRUSTACI, S ^{[1
]}

FOLADORE, S ^{[1
]}

LORE, G ^{[1
]}

MORASSUT, S ^{[1
]}

MONFARDINI, S ^{[1
]}

机构：

[1] CTR RIFERIMENTO ONCOL,DEPT RADIOL,AVIANO,ITALY

来源：

TUMORI | 1990年 / 76卷 / 03期

关键词：

D O I：

10.1177/030089169007600305

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A combination of platinum (100 mg/m2 in a 24-h continuous i.v. infusion) and mitomycin C (10 mg/m2 i.v. push at the end of the cisplatin infusion) was administered in 20 patients with advanced breast cancer refractory to conventional treatments (CMF and anthracycline-containing regimens, hormonal therapies). The response rate was 20% (4/20), including one complete response of lung metastases which lasted 12 months. Median duration of partial responses was 4 months. Major toxicity was gastrointestinal and it was superimposable to that observed with other cisplatin-containing regimens. A marked and prolonged asthenia was reported in 6/20 patients (30%), and the regimen's compliance was poor. We conclude that at these doses and schedule, the cisplatin and mitomycin C combination has a limited efficacy in advanced breast cancer patients, and its use is not recommended in pretreated patients.

引用

页码：234 / 237

页数：4

共 19 条

[1]

CARBONE PP, 1978, SEMIN ONCOL, V5, P417

[2] PLATINUM AND ETOPOSIDE IN CHEMOTHERAPY REFRACTORY METASTATIC BREAST-CANCER - A PHASE-II TRIAL OF THE ITALIAN ONCOLOGY GROUP FOR CLINICAL RESEARCH (GOIRC) [J].